| Ms Kerry-ann Alyscia Kelly, MD | |
|
2500 Merced St, Ob/gyn Department, San Leandro, CA 94577-4201 | |
| (510) 454-4090 | |
| Not Available |
| Full Name | Ms Kerry-ann Alyscia Kelly |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 13 Years |
| Location | 2500 Merced St, San Leandro, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023367141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | A126079 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alameda Health System | 3779494521 | 504 |
News Archive
inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.
Between 2012 and 2014, over 70 companies globally valued at more than $1 billion were start-ups with new business models that were unique and transformative. During the same period, most business model innovators have managed to produce consistently profitable returns with average revenue gain between 100 and 500 percent. The keys to these success stories have been connectivity and convergence with 50 percent of new start-ups launched on mobile platforms.
A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo.
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).
› Verified 4 days ago
| Entity Name | Alameda Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740332931 PECOS PAC ID: 3779494521 Enrollment ID: O20031110000764 |
News Archive
inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.
Between 2012 and 2014, over 70 companies globally valued at more than $1 billion were start-ups with new business models that were unique and transformative. During the same period, most business model innovators have managed to produce consistently profitable returns with average revenue gain between 100 and 500 percent. The keys to these success stories have been connectivity and convergence with 50 percent of new start-ups launched on mobile platforms.
A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo.
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).
› Verified 4 days ago
| Entity Name | Obhg California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215258892 PECOS PAC ID: 8729276795 Enrollment ID: O20101217000826 |
News Archive
inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.
Between 2012 and 2014, over 70 companies globally valued at more than $1 billion were start-ups with new business models that were unique and transformative. During the same period, most business model innovators have managed to produce consistently profitable returns with average revenue gain between 100 and 500 percent. The keys to these success stories have been connectivity and convergence with 50 percent of new start-ups launched on mobile platforms.
A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo.
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kerry-ann Alyscia Kelly, MD 2500 Merced St, Ob/gyn Department, San Leandro, CA 94577-4201 Ph: (510) 454-4090 | Ms Kerry-ann Alyscia Kelly, MD 2500 Merced St, Ob/gyn Department, San Leandro, CA 94577-4201 Ph: (510) 454-4090 |
News Archive
inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.
Between 2012 and 2014, over 70 companies globally valued at more than $1 billion were start-ups with new business models that were unique and transformative. During the same period, most business model innovators have managed to produce consistently profitable returns with average revenue gain between 100 and 500 percent. The keys to these success stories have been connectivity and convergence with 50 percent of new start-ups launched on mobile platforms.
A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo.
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).
› Verified 4 days ago
Clara Lee, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Stephanie Kong, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-807-1557 | |
Marie Louise La Cour, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Colleen Marie Kavanagh, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Alicia Pamela Sinclair, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Leslie Gendler Wilkof, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 |